Investment Management Associates Inc. ADV Takes Position in Elevance Health, Inc. $ELV

Investment Management Associates Inc. ADV purchased a new position in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,108 shares of the company’s stock, valued at approximately $4,235,000. Elevance Health accounts for approximately 1.2% of Investment Management Associates Inc. ADV’s investment portfolio, making the stock its 20th largest holding.

Several other institutional investors also recently bought and sold shares of ELV. Physician Wealth Advisors Inc. lifted its holdings in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares during the period. Activest Wealth Management increased its holdings in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the period. Vermillion & White Wealth Management Group LLC raised its position in shares of Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after acquiring an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new stake in shares of Elevance Health during the 2nd quarter worth $32,000. Finally, Motco lifted its stake in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 77 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ELV. Wolfe Research set a $425.00 target price on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Robert W. Baird raised their price target on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Jefferies Financial Group cut their price objective on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Stock Performance

Shares of ELV opened at $325.61 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The stock has a 50-day moving average of $351.86 and a two-hundred day moving average of $331.28. The stock has a market cap of $71.87 billion, a P/E ratio of 12.96, a P/E/G ratio of 1.82 and a beta of 0.50. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the prior year, the company earned $3.84 earnings per share. The company’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.